Maravai LifeSciences (MRVI) Stock: Buy, Sell, or Hold?
MRVI - Maravai LifeSciences Holdings, Inc. Class A Common Stock
$6.53
-0.20 (-2.97%)
▼
5d:
-11.4%
30d:
+12.98%
90d:
+25.34%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When MRVI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: MRVI is down 11.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: MRVI is down 11.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: MRVI is currently trading at $6.53, which is considered fair relative to its 30-day fair value range of $5.99 to $8.03.
Technical Outlook: Technically, MRVI is in a strong uptrend. The price is currently testing key support at $6.49. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MRVI scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.30 (+11.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MRVI is in a strong uptrend. The price is currently testing key support at $6.49. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MRVI scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.30 (+11.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$5.99 -
$8.03
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.4%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($7.30)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.99 -
$8.03
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$6.49
Resistance Level
$8.18
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-65.04
Wall Street Target
$7.30
(+11.8%)
Revenue Growth (YoY)
8.5%
Earnings Growth (YoY)
-32.7%
Profit Margin
-37.1%
Share & Embed Analysis
Last updated: September 11, 2026 10:52 PM ET
Data refreshes hourly during market hours. Next update: 11:52 PM
Data refreshes hourly during market hours. Next update: 11:52 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MRVI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
